China's MingSight and Relin link up to develop treatment for diabetic eye disease

7 July 2011

Two leading Chinese ophthalmic specialists, Shenzhen Relin Medicine and MingSight Pharmaceuticals, have set up a joint venture, Jiangsu MingSight-Relin Pharmaceutical, to develop and commercialize an innovative treatment for diabetic retinopathy in China. Financial details of the joint venture were not disclosed.

MingSight-Relin, registered in Taizhou, Jiangsu, is focused on developing MS-553, a New Chemical entity that has the potential to become a first-in-class oral therapy for diabetic eye disease. MingSight-Relin acquired the exclusive rights in China to MS-553 from MingSight, which previously in-licensed the compound from Pfizer through an exclusive worldwide licensing agreement.

Safety and potency demonstrated in trials by Pfizer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK